PPS Mobile - Industry News

Home | Industry News | Health Canada Advisories

Doribax (doripenem for injection) - Higher Mortality Rate and a Lower Clinical Cure Rate Observed During a Comparative Clinical Trial - Janssen Inc.
- Notice to Hospitals [2012-01-31]
VELCADE (bortezomib) - Fatal if Given Intrathecally - Janssen Inc.
- For Health Professionals [2012-01-31]
Celexa (citalopram) - Association with abnormal heart rhythms - Lundbeck Canada Inc.
- For Health Professionals [2012-01-30]
- For the Public [2012-01-30]
Duet TRS Loading Units (Used with Endo GIA Universal Staplers and Endo GIA Universal Ultra Staplers) - Urgent Medical Device Recall - Contraindication for Thoracic Use - Covidien Canada
- Notice to Hospitals [2012-01-25]
RASILEZ (aliskiren) and RASILEZ HCT (aliskiren/hydrochlorothiazide) - Potential Risks of Cardiovascular and Renal Adverse Events in Patients with Type 2 Diabetes - Novartis Pharmaceuticals Canada Inc.
- For Health Professionals [2012-01-23]
- For the Public [2012-01-23]
Champix: Updated safety information for the smoking-cessation drug [2012-01-19]

"Compliments Muscle and Back Pain Relief Regular Strength": Labelling Error May Pose Serious Risks to Children [2011-12-29]
North American Urgent Recall: Neonatal, Pediatric and Flextend Tracheostomy Tubes [2011-12-23]
EpiPen and EpiPen Jr Auto-Injectors - Important Safety Information on Correct Usage - Pfizer Canada Inc.
- For Health Professionals [2011-12-22]
- For the Public [2011-12-22]
Rasilez (aliskiren): Health Canada reviewing safety of blood-pressure drug [2011-12-22]
Bisphosphonate osteoporosis drugs (Aclasta, Actonel, Didrocal, Fosamax, Fosavance): Small but increased risk of unusual thigh bone fractures [2011-12-19]
Multaq (dronedarone) - Information on Important Revisions to Product Monograph - Sanofi-aventis Canada Inc.
- For Health Professionals [2011-12-08]
- For the Public [2011-12-08]
AVASTIN (bevacizumab) - Reports of Cases of Severe Eye Inflammation Leading to Blindness Following Use in the Eye - Hoffmann-La Roche Ltd.
- For Health Professionals [2011-12-07]
- For the Public [2011-12-07]
Ursodiol (ursodeoxycholic acid, UDCA) - Association of High-Dose with Serious Liver Side Effects - Aptalis Pharma Canada Inc., Dominion Pharmacal, Pharmascience Inc., Pharmel Inc., Teva Canada Ltd.
- For Health Professionals [2011-12-05]
- For the Public [2011-12-05]
Sublinox (zolpidem tartrate) - Association with complex sleep behaviours - Meda Valeant Pharma Canada Inc.
- For Health Professionals [2011-12-05]
- For the Public [2011-12-05]

"Stiff One Hard 169" Recalled From the Canadian Market: May Pose Serious Health Risks to Canadians [2011-11-30]
Avastin (bevacizumab) - Health Canada has Suspended Approval for Use in Metastatic Breast Cancer - Hoffmann-La Roche Ltd.
- For Health Professionals [2011-11-29]
CooperVision Expands List of Contact Lenses [2011-11-16]
Avastin (bevacizumab) - Higher Incidence of New Cases of Ovarian Failure Observed in Premenopausal Women - Hoffmann-La Roche Limited
- For Health Professionals [2011-11-14]
- For the Public [2011-11-14]
Pradax (dabigatran etexilate) and Plavix (clopidogrel bisulfate) - Risk of Potential Patient Harm Associated with Brand Name Confusion - Boehringer Ingelheim (Canada) Ltd. and sanofi-aventis Canada Inc.
- For Health Professionals [2011-11-08]
- For the Public [2011-11-08]
Fluoroquinolone antibiotics: patients with myasthenia gravis may risk increased muscle weakness [2011-11-07]

Xigris (drotrecogin alfa [activated]) - Worldwide Withdrawal - Eli Lilly Canada Inc.
- For Health Professionals [2011-10-28]
- Notice to Hospitals [2011-10-28]
- For the Public [2011-10-28]
SynchroMed II Implantable Drug Infusion Pumps - Urgent Medical Device Correction Letter - Medtronic of Canada Ltd.
- For Health Professionals [2011-10-26]
Xigris (drotrecogin alfa) withdrawn worldwide [2011-10-25]
STRATTERA (atomoxetine) - Association with Increased Blood Pressure and Increased Heart Rate - Eli Lilly Canada Inc.
- For Health Professionals [2011-10-24]
- For the Public [2011-10-24]
Citalopram: Health Canada reviewing dose-related heart risk [2011-10-13]